Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 2003

View Archived Issues

New data on the efficacy and safety of vardenafil in erectile dysfunction

S-18886 improves endothelial function in coronary artery disease

Potential noninvasive technique for the detection of Alzheimer's disease

Boehringer Ingelheim presents new cathepsin inhibitors with utility in autoimmune diseases

Porphyrin-based photosensitizers for use in ocular disorders, cancer, etc.

Novel neurotrophic agents prepared and tested at Ortho-McNeil

Schering patent covers new CDK and/or GSK-3beta inhibitors

Bayer researchers describe new PPARalpha agonists and their use in coronary heart disease

Antitumor apoptolidin derivative with enhanced stability

Analgesic agents with neurotensin NT2 receptor-antagonist activity

Roche scientists prepare and test novel COX-2 inhibitors

CytRx expands RNAi collaboration with Massachusetts medical school

Yamanouchi licenses PYM-50028 rights for Japan

Phase I trial of HER-2 Protein AutoVac cleared to begin

Elan: Q1 developments

First-quarter results reported by Aventis

InterMune offers review of Q1 highlights

FDA grants accelerated approval of Iressa for NSCLC

Viventia's first armed antibodies to enter phase I clinical testing

Positive preclinical results reported for new treatment for sepsis

Roscovitine inhibits the proliferation of RPE cells

Cell adhesion inhibitor K-7174 exerts beneficial effects in murine model of Sjogren's syndrome

U.S. approval for Cialis anticipated for second half of 2003

Further positive results from FluINsure challenge study

Riquent NDA filing planned

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...